AIMS/HYPOTHESIS: Clear evidence exists that TNF-alpha inhibits insulin signalling and thereby glucose uptake in myocytes and adipocytes. However, conflicting results exist with regard to the role of TNF-alpha in type 2 diabetes. METHODS: We obtained blood and biopsy samples from skeletal muscle and subcutaneous adipose tissue in patients with type 2 diabetes (n = 96) and healthy controls matched for age, sex and BMI (n = 103). RESULTS: Patients with type 2 diabetes had higher plasma levels of fasting insulin (p < 0.0001) and glucose (p < 0.0001) compared with controls, but there was no difference between groups with regard to fat mass. Plasma levels of TNF-alpha (p = 0.0009) and soluble TNF receptor 2 (sTNFR2; p = 0.002) were elevated in diabetic patients. Insulin sensitivity was correlated with quartiles of plasma TNF-alpha after adjustment for age, sex, obesity, WHR, neutrophils, IL-6 and maximum O(2) uptake (VO2/kg) in the diabetes group (p < 0.05). The TNF mRNA content of adipose or muscle tissue did not differ between the groups, whereas muscle TNF-alpha protein content, evaluated by western blotting, was higher in type 2 diabetic patients. Immunohistochemistry revealed more TNF-alpha protein in type 2 than in type 1 muscle fibres. CONCLUSIONS/ INTERPRETATION: After adjustment for multiple confounders, plasma TNF-alpha is associated with insulin resistance. This supports the idea that TNF-alpha plays a significant role in the pathogenesis of chronic insulin resistance in humans. However, findings on the TNF-alpha protein levels in plasma and skeletal muscle indicate that measurement of TNF mRNA content in adipose or muscle tissue provides no information with regard to the degree of insulin resistance.
AIMS/HYPOTHESIS: Clear evidence exists that TNF-alpha inhibits insulin signalling and thereby glucose uptake in myocytes and adipocytes. However, conflicting results exist with regard to the role of TNF-alpha in type 2 diabetes. METHODS: We obtained blood and biopsy samples from skeletal muscle and subcutaneous adipose tissue in patients with type 2 diabetes (n = 96) and healthy controls matched for age, sex and BMI (n = 103). RESULTS:Patients with type 2 diabetes had higher plasma levels of fasting insulin (p < 0.0001) and glucose (p < 0.0001) compared with controls, but there was no difference between groups with regard to fat mass. Plasma levels of TNF-alpha (p = 0.0009) and soluble TNF receptor 2 (sTNFR2; p = 0.002) were elevated in diabeticpatients. Insulin sensitivity was correlated with quartiles of plasma TNF-alpha after adjustment for age, sex, obesity, WHR, neutrophils, IL-6 and maximum O(2) uptake (VO2/kg) in the diabetes group (p < 0.05). The TNF mRNA content of adipose or muscle tissue did not differ between the groups, whereas muscle TNF-alpha protein content, evaluated by western blotting, was higher in type 2 diabeticpatients. Immunohistochemistry revealed more TNF-alpha protein in type 2 than in type 1 muscle fibres. CONCLUSIONS/ INTERPRETATION: After adjustment for multiple confounders, plasma TNF-alpha is associated with insulin resistance. This supports the idea that TNF-alpha plays a significant role in the pathogenesis of chronic insulin resistance in humans. However, findings on the TNF-alpha protein levels in plasma and skeletal muscle indicate that measurement of TNF mRNA content in adipose or muscle tissue provides no information with regard to the degree of insulin resistance.
Authors: Christian P Fischer; Lisbeth B Perstrup; Annika Berntsen; Peter Eskildsen; Bente K Pedersen Journal: Clin Immunol Date: 2005-08-19 Impact factor: 3.969
Authors: V Mohamed-Ali; S Goodrick; A Rawesh; D R Katz; J M Miles; J S Yudkin; S Klein; S W Coppack Journal: J Clin Endocrinol Metab Date: 1997-12 Impact factor: 5.958
Authors: Vesna Boraska; Nigel W Rayner; Christopher J Groves; Timothy M Frayling; Mahamadou Diakite; Kirk A Rockett; Dominic P Kwiatkowski; Aaron G Day-Williams; Mark I McCarthy; Eleftheria Zeggini Journal: BMC Med Genet Date: 2010-05-06 Impact factor: 2.103
Authors: Charmaine S Tam; Alexander Viardot; Karine Clément; Joan Tordjman; Katherine Tonks; Jerry R Greenfield; Lesley V Campbell; Dorit Samocha-Bonet; Leonie K Heilbronn Journal: Diabetes Date: 2010-06-14 Impact factor: 9.461
Authors: Ole Hartvig Mortensen; Anders Rinnov Nielsen; Christian Erikstrup; Peter Plomgaard; Christian Philip Fischer; Rikke Krogh-Madsen; Birgitte Lindegaard; Anne Marie Petersen; Sarah Taudorf; Bente Klarlund Pedersen Journal: PLoS One Date: 2009-10-12 Impact factor: 3.240
Authors: Rachana Shah; Yun Lu; Christine C Hinkle; Fiona C McGillicuddy; Roy Kim; Sridhar Hannenhalli; Thomas P Cappola; Sean Heffron; XingMei Wang; Nehal N Mehta; Mary Putt; Muredach P Reilly Journal: Diabetes Date: 2009-07-06 Impact factor: 9.461
Authors: Evros K Vassiliou; Andres Gonzalez; Carlos Garcia; James H Tadros; Goutam Chakraborty; Jeffrey H Toney Journal: Lipids Health Dis Date: 2009-06-26 Impact factor: 3.876